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"Nephritic flares" are predictors of bad long-term renal outcome
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"Nephritic flares" are predictors of bad long-term renal outcome in
lupus ncphritis. We retrospectively analyzed the courses of 70 patients
with lupus nephritis followed for 5 to 30 years (median 127 months).
Patient survival was 100% at 10 years and 86% at 20 years. The probability
of not reaching the end point (persistent doubling of plasma creatinine)
was 85% at 10 years and 72% at 20 years. A multivariate analysis of
variables at presentation showed that male sex (P = 0.005) and hematocrit
lower than 36% (P = 0.01) were associated with the end point (relative
risk 7.5 and 14). We then analyzed for the role of renal flare-ups, defined
either as a rapid increase in plasma creatinine or by an increase in
proteinuria. Patients with renal flares of any type had more probabilities of
reaching the end point than patients who never had flares (P = 0.03;
relative risk 6.8). The hazard of the end point was 27 times higher in
patients with flares along with rapid increased in plasma creatinine than in
patients without flares or with flares with proteinuria alone (P < 0.00001).
Ibis hazard was higher when plasma creatinine did not return to the basal
levels within two months after treatment (P < 0.0001).
Renal disease is a frequent complication of systemic lupus
erythematosus (SLE) that can heavily influence the prognosis.
The mortality rate is higher for SLE patients with nephritis than
for those without renal involvement [1, 2], and some 10 to 60% of
SLE patients with nephritis eventually develop end-stage renal
disease [3—8]. A number of studies have looked for which clinical
and histological features at presentation might be predictive of
outcome in the long-term. However, the conclusions of these
studies have not all agreed [5—20]. This was not completely
unexpected, in view of the different criteria for selection, the
heterogeneity of the disease and the different therapeutic sched-
ules used.
In this study we reviewed the outcome of 70 patients with lupus
nephritis, all of whom had had follow-ups of at least five years.
The initial outcome of 21 of these patients was reported before
[21]. All patients were submitted to renal biopsy, were followed by
a single institution and were given treatment with homogeneous
criteria. For this particular series, we investigated not only the
prognostic value of clinical and histological features at presenta-
tion but also the possible prognostic role of exacerbations of lupus
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Criteria for inclusion in this study were: (i) a histological
diagnosis of lupus nephritis with a daily urine protein excretion of
more than 1 g per day, and/or an elevated plasma creatinine; (ii)
four or more signs and symptoms of SLE [22]; (iii) a follow-up of
at least five years. Patients with a creatinine clearance lower than
20 mI/mm for more than three months prior to admission were
excluded. According to these criteria three patients with rapidly
progressive glomerulonephritis and creatinine clearance between
8 and 15 mI/mm were included, while eight patients with chronic
renal failure were not admitted. All these eight patients reached
the end-stage renal disease in a median period of one month.
Glomerular lesions were classified according to the WHO classi-
fication [23]. The activity and chronicity indices were assessed
according to Austin et al [16].
Patients were evaluated clinically and biochemically at least
once a month if any sign or symptom of renal activity was present.
Patients with normal plasma ereatinine, proteinuria less than 0.2 g
per day, and inactive urine sediment were evaluated every three to
six months and whenever patients complained of any symptom.
Definitions
The end point of the study was defined as the doubling of
plasma creatinine lasting for at least six months with a value of
plasma creatinine of at least 2 mg/dl. Renal insufficiency was
defined as plasma creatinine equal to or higher than 1.5 mg/dl.
Complete remission was defined as proteinuria less than 0.2 g per
day, with normal renal function. Nephrotic proteinuria was de-
fined by a daily urine protein excretion of more than 3.5 g per day;
non-nephrotic proteinuria was defined as urinary protein excre-
tion between 0.2 and 3.5 g per day. Arterial hypertension was
defined as a supine diastolic blood pressure higher than 90 mm Hg
in three consecutive measurements. Serum C3 levels lower than
55 mg/dl and serum C4 levels lower than 20 mg/dl were considered
to be low.
A renal flare-up was arbitrarily defined as: (i) "nephritic flare"
characterized by an increase in plasma creatinine of at least 30%
over the last value associated with nephritic urinary sediment and
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generally increased proteinuria. This definition did not include
patients with chronic slower increase in plasma creatinine who
were considered not to have "nephritic flare" but as having a
progressive chronic renal failure. (ii) "Proteinuric flare" was
characterized by an increase in proteinuria without modification
of plasma creatinine. Proteinuria had to increase by at least 2 g
per day if the basal proteinuria was less than 3.5 g per day, or be
doubled if patient already had a nephrotic proteinuria [21].
Therapy
Three patients with normal renal function and non-nephrotic
proteinuria were never treated during the follow-up. In two of
them who were diagnosed with membranous nephritis, one fol-
lowed for 11 and one for 14 years, proteinuria slowly decreased
until complete remission. In the third patient, with focal prolifer-
ative nephritis, proteinuria persisted around 1 g per day until the
last observation, five years after presentation. One patient with
membranous nephropathy and non-nephrotic proteinuria was not
treated for six years. Then nephrotic syndrome developed and the
patient was submitted to three intravenous methylprednisolone
pulses followed by oral prednisone, 0.5 mg/kg per day.
Nineteen patients admitted to our Unit before 1976 (10 with
diffuse proliferative nephritis, 7 with membranous nephritis and 2
with focal proliferative nephritis) were given oral prednisone, 1
mg/kg per day for one month, gradually reduced to a maintenance
dose of 10 to 15 mg per day. In this group, 13 patients with more
severe renal and extrarenal disease were also treated with immu-
nosuppressive agents: 8 patients were given azathioprine for a
median period of 11.5 months (25th and 75th percentile, 8.7 and
12), 1 patient was given chlorambucil for six months, 4 patients
were given oral cyclophosphamide for a median period of eight
months (25th and 75th percentile, 3.7 and 12). Another 47
patients were admitted to our Unit after 1976 (32 with diffuse
proliferative nephritis, 11 with membranous nephritis and 4 with
focal proliferative nephritis). All of them were initially treated
with three consecutive intravenous methylprednisolone pulses
(0.5 to I g every 24 hr according to the body wt) followed by oral
prednisone (0.5 to 1 mg/kg per day), gradually tapered to 10 to 15
mg per day as maintenance therapy. For 29 patients with more
severe renal and extrarenal disease, immunosuppressive agents
were added: azathioprine for 12 patients for a median period of
seven months (25th and 75th percentile, 5.7 and 10), chlorambucil
for 11 patients for a median period of three months (25th and 75th
percentile, 1.5 and 4), oral cyclophosphamide for 6 patients for a
median period of two months (25th and 75th percentile, 1 and 3).
Before 1976, the flare-ups were treated with prednisone, 1
mg/kg per day for 15 to 30 days, then gradually tapered; after 1976
the flare-ups were treated with three intravenous methylpred-
nisolone pulses (0.5 to 1 g each), followed by a reinforcement of
oral prednisone (0.5 to 1 mg/kg per day) and by the introduction
of immunosuppressive agents for the more severe cases.
Statistical analysis
The study end point was the persistent doubling of plasma
creatinine. For the two patients who died, the last plasma
creatiriine before death was considered. The following clinical and
histological parameters at study entry were analyzed for predictive
value: duration of lupus nephritis before admission, sex, age,
serum creatinine, daily urine protein excretion, arterial hyperten-
sion, serum albumin levels, hematocrit, platelets, blood white
cells, serum C3 levels, serum C4 levels, number of extra-renal
symptoms, WHO histological classification, activity index, chro-
nicity index. In addition, the predictive value of nephritic flares
was analyzed. The above-mentioned clinical and histological
factors were evaluated for the prediction of renal flares together
with therapeutic strategies (treatment with or without methyl-
prednisolone pulses, amount of prednisone at 3, 6, 12 months,
treatment with of without cytotoxic agents). Data management
and analysis were performed with the S-Plus Statistical Package
[24]. Median and interquartile range values were used as descrip-
tive statistics, because of the non-normal distribution of most
variables. The non-parametric Wilcoxon test was used to compare
two sample medians of continuous variables. The cumulative
survival curves were derived by the Kaplan-Meier method [25],
and the differences between two survival curves were checked by
the log-rank or Mantel-Haenszel test [26]. The influences of
prognostic factors on the risk for both chronic renal failure and
nephritic flares with rapid increase in plasma creatinine were
investigated by the Cox proportional hazard regression model
[27]. Both uni- and multivariate analyses were performed. The
Harrell z-test on Schoenfeld residuals was used to examine the
proportional hazard assumption for each covariate [28]. Logarith-
mic transformation was used on variables showing skewed distri-
bution, before entering them in the regression models. Model
selection was performed by heuristic searches through a number
of candidate models. Stepwise regression algorithms were not
used, because the sample size was not large enough to guarantee
the reliability of automatically selected models. A threshold value
was found for some of the continuous variables that were signif-
icant at the univariate Cox regression model: the threshold was
defined as the value that maximized, with the least group size
imbalance, the difference between the survival curves of the
groups of patients individualized by the value itself. It is clear that
different thresholds could be found for the same variable when
predicting different outcomes.
Relative risks and their 95% confidence interval (CI) have been
derived, after fitting the Cox propotional hazards model, as the
antilogarithm of the coefficient estimated for each covariate
included in the model. As an alternative procedure, the relative
risk due to a binary variable has been calculated using the log-rank
approach, that is, computing the ratio between the differences
(observed failures — expected failures) in the two patient groups
indivituated by the variable itself. Very similar results were
obtained by the two methods, and in the following only those
derived from Cox model will shown.
Results
Clinical characteristics at presentation
Seventy patients (65 female and 5 male), median age 28.5 (25th
and 75th percentile, 21 and 33) entered this study. The median
duration of lupus nephritis before admission was three months
(25th and 75th percentile, 0.2 and 7.1). Twenty-one patients
(30%) had renal insufficiency at presentation (median plasma
creatinine 1.8 mg/dl, 25th and 75th percentile, 1.6 and 2.4). All
had proteinuria (median 3.3 g per day; 25th and 75th percentile,
1.8 and 4.9), which was in a riephrotic range in 33 patients (47%).
Twenty-four patients (34%) had arterial hypertension. Serum C3
was low in 42 patients and serum C4 in 46 (Table 1). Renal
biopsies showed diffuse proliferative nephritis (Class IV) in 42
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end point (56) pa
Duration of renal disease before 3 2.5 3.0 0.46
study entry, months (m)
Sex 0.003
men(N) 5 4 1
women (N) 65 10 55
Age, years (m) 28.5 29 27.5 0.84
Serum ereatinine, mg/dl (m) 1 1.55 0.9 0.09
Proteinuria, giday (m) 3.3 3.5 3.1 0.7
Arterial hypertension (N) 24 7 17 0.15
Albumin, gidi (m) 2.7 2.95 2.7 0.23
Hematocrit 0.0015
< 36% (N) 37 13 24
36%(N) 33 1 32
Platelet count, 1mm3 (m) 224000 200000 240000 0.97
White blood cells count, 1mm3 5550 5800 5350 0.4
(m)
Low C3 (N) 42 8 34 0.5
Low C4 (N) 46 9 37 0.9
Extrarenal symptoms (m) 3.0 3.5 3.0 0.07
W.H.O. 0.2
111(N) 7 0 7
IV(N) 42 9 33
V(N) 21 5 16
Activity index (m) 7 6 7.5 0.3
Chronicity index 0.02
5(N) 8 3 5
<5(N) 62 ii 51
Values are expressed either as number of patients (N) or as median (m).
aP values refer to the statistical significance of the variables either in the Cox proportional hazard regression (for a continuous variable) or in the
log-rank test for survival curves difference (for a discrete or discretized variable).
patients, focal proliferative nephritis (Class 111) in 7 patients, and
membranous nephritis (Class V) in 21 patients. The median
activity index was 7 (25th and 75th percentile, 2 and 10) and the
median chronicity index was 2 (25th and 75th percentile, 0.5 and
10). At presentation arthralgias were present in 66 patients (94%),
fever in 54 patients (77%), cutaneous involvement in 53 patients
(76%), pericarditis in 14 patients (20%), pleuritis in 13 patients
(19%), and cerebritis in 8 patients (12%).
Outcome
Patients were followed for 5 to 30 years (median 127 months;
25th and 75th percentile, 90 and 181). The patient survival rate
was 100% at 5 and 10 years and 86% at 20 years. Two patients
died, one of cerebral hemorrhage after 115 years and one of lung
cancer after 12 years of observation, when their plasma creat-
mines were 2.8 and 0.9 mg/dl. The probability of not reaching the
end point was 94% at five years, 85% at 10 years and 72% at 20
years (Fig. 1). Fourteen patients (20%) reached the end point
after a median period of observation of 119 months (25th and 75th
percentile, 77 and 139.6). Four of them had to be submitted to
dialysis; the other 10 patients had a median plasma ereatinine of
2.3 mg/dl (25th and 75th percentile, 2 and 3) at the last observa-
tion. The remaining 56 patients had a median plasma creatinine of
0.8 mg/dI (25th and 75th percentile, 0.7 and 0.9) after a median
follow-up of 125 months (25th and 75th percentile, 86.1 and
175.6). At the last observation, 27 of these patients had been in
complete remission for a median period of 86.2 months (25th and
75th percentile, 40.6 and 117.6), 27 had non -nephrotic proteinuria
(median 1.2 g per day; 25th and 75th percentile, 0.6 and 1.8) and
2 had nephrotic proteinuria (3.5 and 4.2 g per day; Table 2).
A univariate analysis was performed to see whether any clinical
or histological data at presentation might predict the long-term
renal outcome. Male sex (P = 0.003), chronicity index higher than
5 (P = 0.02) and hematocrit lower than 36% (P = 0.0015) at
presentation were significantly associated with the probability of







Fig. 1. Probability of patients survival (A) and probability of patients
survival without end point (persistent doubling of plasma creatinine) (solid
line). Numbers on the curves indicate the number of patients who remain
at risk.
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Table 2. Clinical status at the last follow-up
male sex (P = 0.005) and low hematocrit (P = 0.01) were
significantly associated with the end point. We checked for other
threshold values but could not find any other significant cutpoint
leading to less imbalance among groups both in univariate and
multivariate analysis. A chronicity index of 6 was significant at
multivariate analysis (P = 0.01), but the use of this cutpoint would
have futher increased the imbalance between groups (5 vs. 63).
The relative risk of reaching the end point was 7.5 for men (95%
CI = 1.85 to 30.7) and 14 for patients with hematocrits lower than
36% (95% CI = 1.85 to 110.9).
Renal flares
Twenty-four patients (2 with focal proliferative nephritis, 12
with diffuse proliferative nephritis, 10 with membranous nephri-
tis) never had renal flares during the median follow-up of 127
months (25th and 75th percentile, 84 and 186). The other 46
patients (5 with focal proliferative nephritis, 30 with diffuse
proliferative nephritis, 11 with membranous nephritis) developed
114 renal flares during a median follow-up of 128 months (25th
and 75th percentile, 99 and 177), which means 0.22 flare/patient!
year. Twenty-one patients (1 with focal proliferative nephritis, 15
with diffuse proliferative nephritis, 5 with membranous nephritis)
had 37 nephritic flares with a rapid change in renal function plus
25 flares with a change in proteinuria. The other 25 patients (4
with focal proliferative nephritis, 15 with diffuse proliferative
nephritis, 6 with membranous nephritis) had 52 flares with a
change in proteinuria.
In the group of patients who had no flares, only one patient
(4%) reached the end point (plasma creatinine 2.3 mg/dl) after a
follow-up of 87 months. The other 23 patients had a median
plasma creatinine of 0.8 mg/dl (25th and 75th percentile, 0.7 and
0.9) after a median observation of 128 months (25th and 75th
percentile, 80.1 and 188.2). At the last observation, two patients
had non-nephrotic proteinuria (below I g per day in both) and 21
(87.5%) had been in complete remission for a median period of 86
months (25th and 75th percentile, 44.6 and 116.6; Table 2).
Twenty-one patients had 37 flares with rapid increases in
plasma creatinine. In 3 of the 5 patients with membranous
nephritis who developed such a type of flare, a control renal
biopsy was done that showed transformation to diffuse prolifera-
tive nephritis in I patient and to diffuse proliferative nephritis plus
membranous nephritis in 2 patients. The response was assessed
two months after therapy. In 17 flares, the plasma creatinine
returned to basal values after therapy; in 20 flares, the plasma
creatinine remained above the basal values in spite of treatment.
After a median period of observation of 120 months (25th and
75th percentile, 76 and 140), 13 (62%) of the 21 patients with
nephritic flares had reached the end point. This happened less
frequently in patients with complete responses to therapy (P <
0.0001). In 4 of these 13 patients, several flares characterized by
proteinuria alone preceded the nephritic flares with increased
plasma creatinine. Four patients had to be submitted to renal
replacement therapy; the other nine patients had a median plasma
creatinine of 2.5 mg!dl (25th and 75th percentile, 2.1 and 3.1) at
the last observation. The remaining 8 patients who had nephritic
flares had a median plasma creatinine of 0.9 mg/dl (25th and 75th
percentile, 0.8 and 1) after a median follow-up of 123 months
(25th and 75th percentile, 60 and 275). Six of these patients had
non-nephrotic proteinuria (median 1.2 g/day; 25th and 75th
percentile, 0.5 and 2) and 2 (10%) had been in complete
remission, one for 117 and one for 157 months. No patient with
flares characterized by proteinuria alone reached the end point.
At the last observation (median 118 months; 25th and 75th
percentile, 86 and 140), the median plasma creatinine was 0.8
mg!dl (25th and 75th percentile, 0.7 and 0.9), 2 patients had
nephrotic proteinuria, 19 patients had non-nephrotic proteinuria
(median 1.4 g per day; 25th and 75th percentile, 0.6 and 1.7) and
4 patients had been in complete remission for 7, 11, 37, 91 months,
respectively (Table 2).
Since the median follow-ups of patients who had (128 months;
25th and 75th percentile, 99 and 177) or did not have renal flares
(127 months; 25th and 75th percentile, 84 and 186; P = NS) were
similar, the survival curves of these two groups were compared
(Fig. 2). Patients who developed renal flares had significantly
greater probabilities of reaching the end point than patients who
never flared (P = 0.03, relative risk 6.8, 95% CI = 0.91 to 53.5).
The median follow-up for patients who developed nephritic flares
(135 months; 25th and 75th percentile, 108 and 200) was similar to
that for the other patients (125 months; 25th and 75th percentile,
87 and 167; P = NS), allowing comparison of the survival curves
of these two groups (Fig. 3). The probability of reaching the end
point was significantly greater for patients with nephritic flares
(P < 0.00001) with a relative risk of 27 (95% CI = 3.8 to 222).
By univariate analysis, the following clinical features at presen-
tation were significantly associated with the risk of developing
nephritic flares: male sex (P = 0.002), plasma creatinine higher
than 1.5 mg/dl (P = 0.0015), arterial hypertension (P = 0.0005),
number of extra-renal symptoms (P = 0.01), and hematocrit lower
than 26% (P = 0.001). By multivariate analysis, only male sex(P = 0.015) and arterial hypertension (P = 0.004) were indepen-
dent predictors of renal flares characterized by increased plasma
creatinine. The relative risk of developing these nephritic flares
was 4 for men (95% CI = 1.3 to 12.8) and 3.8 for patients with
arterial hypertension at presentation (95% CI = 1.54 to 9.33).







(70) renal flares (24) renal flares (46) flares" (25) flares" (21)
Doubling of plasma creatinine" 14 (20%) 1 (4.2%) 13 (28.3%) 0 13 (62%)
Normal renal function with 2 (3%) 0 2 (4.3%) 2 (8%) 0
nephrotic syndrome
Normal renal function and 27 (38.5%) 2 (8.3%) 25 (54.4%) 19 (76%) 6 (28%)
non-nephrotic proteinuria"
Complete remission 27 (38.5%) 21(87.5%) 6 (13%) 4 (16%) 2 (10%)
"One patient per group died, the clinical status at the last follow-up before death is reported
Discussion
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In this series, the outcomes for 70 Italian patients with lupus
nephritis followcd for a minimal period of five years in a single
center were analyzed retrospectively. The extra-renal manifesta-
tions at presentation were similar to that reported by other
authors [3, 29]. The patient survival rate was 100% at 10 years and
86% at 20 years, and the probability of not having a persistent
doubling of plasma ercatinine (the end point of the study) was
94% at five years, 85% at 10 years and 72% at 20 years. Therefore,
most of the events occurred after the fifth year, which permitted
an assessment of the long-term roles of prognostic factors, unlike
most published studies where the fate of patients was heavily
influenced by early deaths or renal failures [5, 6, 8—10, 12—15, 19].
We first evaluated the prognostic role of some clinical, bio-
chemical and histological characteristics of the patients at presen-
tation. When a multivariate analysis was done, only male sex and
anemia were found to be associated with the risk of reaching the
end point. It is well known that lupus nephritis has a worse
prognosis in men than in women [16, 30]. Several studies have also
detected the unfavorable prognostic significance of anemia in
patients with lupus nephritis [9, 11, 14]. Instead, we did not
confirm the prognostic role of elevated plasma creatinine at
presentation reported by others [5,6,9—11, 14, 16, 17]. As pointed
out by some investigators [7, 9, 10, 13] we could not find any
correlation between the histological WHO class at presentation
and the outcome. For our series, however, we excluded patients
with already established severe renal failure. In addition, in our
patients the duration of lupus nephritis before admission to our
Unit was short, so that the increased plasma creatinine at
presentation probably reflected a potentially reversible active
renal disease rather than an irreversible chronic renal insuffi-
ciency. This hypothesis was confirmed by the small number of
Time, years
Fig. 3. Probability of not reaching the end point (persistent doubling of
plasma creatinine) of patients who had "nephritic flares" with a rapid increase
in plasma creatinine (solid line) and of patients who either had no renal flares
or 'roteinuric flares" without changes in renalfhnction (dashed line). The
difference between the two curves is statistically significant (P 0.00001).
Numbers on the top indicate the number of patients at risk.
patients with a high ehronieity index at the initial renal biopsy. On
the other hand, all the studies that found a prognostic role of
initial plasma creatinine [5, 6, 9—11, 14, 16, 17] had mean
follow-ups of no more than five years. The studies with follow-ups
of 10 years or more concluded that there is no association between
initial plasma ereatinine and the final outcome [7, 12, 31]. In
particular, Esdaile et al [7], who used a time-dependent analytic
approach, concluded that increased plasma creatinine at presen-
tation may predict the outcome only for the first years of
observation, but not after five or more years.
The long-term prognostic value of symptoms and signs at
presentation is limited. In fact, the evolution of lupus nephritis is
often unpredictable not only because of large interindividual
variations, but also because the course of the disease may be
variable in the same patient. Some patients who initially have a
mild form of renal involvement may develop hectic activity, while
other patients with initially severe disease may enter stable and
complete remission after adequate therapy. It is also well known
that a number of patients may have a transition from one
histological class to another [32]. To the best of our knowledge, no
study has investigated the prognostic value of renal flares in the
long-term renal evolution of patients with lupus nephritis. In this
study, we considered two types of renal flares, one characterized
by an increase in proteinuria without renal dysfunction and the
other characterized by a rapid increase in plasma creatinine.
Patients who never had flares had a significantly greater number
of stable and complete remissions than patients who did have
renal flares. The relative risk of reaching the end point was also
significantly lower for patients who never had flares. Surprisingly,
no patient with the flares characterized by proteinuria alone
eventually reached the end point. This does not necessarily mean
that these patients will not have any deterioration of renal
---24 14 3 ---49 27 5
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Fig. 2. Probability of not reaching the end point (persistent doubling of
plasma creatinine) of patients who had no renal flares (dashed line) and of
patients who had renal flares of any type (solid line). The difference between
the two curves is statistically significant (P = 0.03). Numbers on the top
indicate the number of patients at risk.
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function in the long-term. As a matter of fact, almost 1/3 of patients
who eventually developed flares with an increase in plasma
creatinine had only flares with change in proteinuria for several
years. The relative risk of reaching the end point was 27 times
greater in patients with the flares characterized by a rapid increase
in plasma creatinine. The complete reversibility of renal dysfunc-
tion after treatment of a flare-up heralded a better prognosis. The
unfavorable influence of renal exacerbations may be due to the
fact that, in spite of therapy, glomerular injury produced by
relapses of SLE may cause lesions that eventually lead to global or
focal glomeruloscierosis [331This evolution might depend on the
severity of the lesions caused by each flare as well as on the
promptness and adequacy of the therapy instituted. Since the
occurrence of renal flares with kidney dysfunction can heavily
influence the outcome of lupus nephritis, it might be useful to
predict which patient will be likely to have a renal flare-up. By
multivariate analysis two variables were significantly associated
with the risk of nephritic flares: male sex and arterial hypertension
at presentation.
In summary, this study confirms the current opinion that the
long-term prognosis of lupus nephritis has considerably improved
in recent years. However, it is clear that the better the long-term
prognosis, the weaker the prognostic significance of clinical
characteristics at presentation. Therefore, it might be better to
look at the activity of the disease during the follow-up to predict
the renal outcome of lupus nephritis in the long-term. In this
study, the occurrence of flares characterized by rapid increases in
plasma creatinine was the strongest predictor of the eventual
development of irreversible deterioration renal function. The
latter event was more likely to occur in patients who did not
respond promptly to therapy. It is thus recommended that all
patients with lupus nephritis, particularly men and hypertensive
patients, continue to be closely monitored in order to catch and
treat early and vigorously any possible deterioration of renal
function caused by flares of SLE activity. These data may indi-
rectly support a therapeutic strategy based on an aggressive
treatment of lupus exacerbation, while sparing corticosteroids and
immunosuppressive agents in the quiescent period to prevent
iatrogenic toxicity. This type of therapy has resulted in good
patient and kidney survival for 20 years and longer in our patients
with lupus nephritis.
Reprint requests to Gabriella Moroni, M.D., Divisione di Nefrologia e
Dialisi, IRCCS Ospedale Maggiore Policlinico, Via Commenda, 15, 20122
Milano, Italy.
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